Summary
2.76 -0.02(-0.72%)09/06/2024
TELA Bio Inc (TELA)
TELA Bio Inc (TELA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.00 | -4.83 | -34.29 | -51.75 | -56.88 | -70.95 | 0.00 | -79.33 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.76 | |
| Open | 2.80 | |
| High | 2.86 | |
| Low | 2.71 | |
| Volume | 42,563 | |
| Change | 0.00 | |
| Change % | 0.00 | |
| Avg Volume (20 Days) | 96,590 | |
| Volume/Avg Volume (20 Days) Ratio | 0.44 | |
| 52 Week Range | 2.54 - 9.60 | |
| Price vs 52 Week High | -71.25% | |
| Price vs 52 Week Low | 8.66% | |
| Range | -1.43 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 68 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 19.00 | |
| Book Value | 1.9120 | |
| Earnings Per Share | -2.2440 | |
| EPS Estimate Current Quarter | -0.5200 | |
| EPS Estimate Next Quarter | -0.5400 | |
| EPS Estimate Current Year | -2.2500 | |
| EPS Estimate Next Year | -1.6800 | |
| Diluted EPS (TTM) | -2.2440 | |
| Revenues | ||
| Profit Marging | -1.2127 | |
| Operating Marging (TTM) | -1.0668 | |
| Return on asset (TTM) | -0.2214 | |
| Return on equity (TTM) | -0.7720 | |
| Revenue TTM | 26,756,000 | |
| Revenue per share TTM | 1.8510 | |
| Quarterly Revenue Growth (YOY) | 0.4410 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 11,538,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.6375 | |
| Revenue Enterprise Value | 6.0446 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 14,503,600 | |
| Shares Float | 5,512,082 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.34 | |
| Institutions (%) | 87.92 | |
08/12 20:37 EST - seekingalpha.com
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2024 Earnings Conference Call. [Operator Instructions].
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2024 Earnings Conference Call. [Operator Instructions].
08/12 18:21 EST - zacks.com
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago.
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago.
08/12 16:05 EST - globenewswire.com
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024.
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024.
08/09 16:05 EST - globenewswire.com
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
07/22 16:05 EST - globenewswire.com
TELA Bio to Announce Second Quarter 2024 Financial Results
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
TELA Bio to Announce Second Quarter 2024 Financial Results
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
06/04 16:05 EST - globenewswire.com
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.
05/20 16:03 EST - globenewswire.com
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines.
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines.
05/11 14:35 EST - seekingalpha.com
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Michael Sarcone - Jefferies Matthew O'Brien - Piper Sandler David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Michael Sarcone - Jefferies Matthew O'Brien - Piper Sandler David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
05/09 16:05 EST - globenewswire.com
TELA Bio Reports First Quarter 2024 Financial Results
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.
TELA Bio Reports First Quarter 2024 Financial Results
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024.
04/25 07:00 EST - globenewswire.com
TELA Bio to Announce First Quarter 2024 Financial Results
MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
TELA Bio to Announce First Quarter 2024 Financial Results
MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
04/15 07:00 EST - globenewswire.com
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.)
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.)
04/08 07:00 EST - globenewswire.com
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery
03/21 19:38 EST - seekingalpha.com
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
03/21 18:31 EST - zacks.com
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.52 per share a year ago.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.52 per share a year ago.
03/21 16:05 EST - globenewswire.com
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.
03/21 07:00 EST - globenewswire.com
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue
03/20 07:00 EST - globenewswire.com
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
TELA Bio to receive at least $8 million and up to $12 million in total consideration TELA Bio to receive at least $8 million and up to $12 million in total consideration
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
TELA Bio to receive at least $8 million and up to $12 million in total consideration TELA Bio to receive at least $8 million and up to $12 million in total consideration
02/29 07:00 EST - globenewswire.com
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report fourth quarter and full year 2023 financial results on Thursday, March 21, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.